A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
CRISPR gene editing has transitioned from a laboratory curiosity to a cornerstone of modern biotechnology, revolutionizing our approach to genetic diseases, including Charcot-Marie-Tooth (CMT) disease ...
Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...
Union Minister of State for Health and Family Welfare, Smt Anupriya Singh Patel recently delivered the keynote address at the 2nd DHR-ICMR Health Research Excellence Summit 2025. Dr V ...
Nitazenes, a class of synthetic drugs 40 times more potent than fentanyl, are steadily becoming more common on both sides of ...
The Global Point-of-Care Molecular Diagnostics Market is projected to grow at a CAGR of 10.2% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals ...
Saudi Arabia’s investments in preventive cardiology and AI-assisted diagnostics, along with increasing awareness of ...
Crop biotechnology is like giving plants superpowers! It’s using science to make plants better, like helping them fight off ...
Nucleic acid testing (NAT) identifies specific pathogen genetic material (DNA or RNA), enabling early and precise diagnosis ...
Zacks Small Cap Research on MSN
DYAI: Purchase Orders Rolling In
DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced third quarter 2025 results on November 12th, 2025, and held a conference call to discuss them after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback